Ovagen is a short synthetic peptide from the Khavinson “bioregulator” family, marketed as an ovarian and reproductive-system regulator for women. It is sold mainly as an oral capsule by longevity and biohacking resellers. Notably, several vendor sites mislabel Ovagen as a liver or gastrointestinal peptide, which conflicts with its stated ovarian/reproductive positioning elsewhere — a discrepancy this page flags rather than resolves silently.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed as an ovarian/female reproductive-system regulator |
| Primary research interest | Ovarian tissue and female reproductive-system function support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — several vendor sites mislabel Ovagen as a liver or gastrointestinal peptide, conflicting with its stated ovarian/reproductive positioning elsewhere; this page flags the discrepancy rather than resolving it silently |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold mainly as an oral capsule by longevity/biohacking resellers |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Ovagen |
| Alternative names | Marketed as part of the Khavinson bioregulator peptide line; conflicting vendor material also labels it a liver/gastrointestinal peptide |
| Peptide sequence | Most commonly given by vendors as Glu-Asp-Leu (“EDL”); could not be confirmed against a primary chemical database |
| Amino-acid length | 3 (tripeptide, per vendor description; not independently confirmed) |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line |
| Primary biological target | Not established — proposed ovarian tissue activity, not confirmed via primary literature; conflicting vendor material also proposes liver/GI activity |
| Developer or originator | Vladimir Khavinson’s laboratory, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Ovagen is part of the same short-peptide bioregulator concept developed by Vladimir Khavinson’s laboratory, in this case proposed to target ovarian tissue and support female reproductive-system function. Vendor listings most often give the sequence as the tripeptide Glu-Asp-Leu (EDL), though this could not be confirmed against a primary chemical database.
A meaningful source conflict exists in the commercial material reviewed for this page: some resellers market Ovagen explicitly as an ovarian/reproductive bioregulator, consistent with its name, while at least one other reseller describes what it labels “Ovagen” as a hepatic (liver) peptide bioregulator. Because these are contradictory organ targets for the same product name, PeptideBlog.net cannot confirm which description is accurate, or whether the liver-labeled product is simply a mislabeling error by that seller. This is documented as an unresolved conflict.
No confirmed CAS number, PubChem CID, or UNII record was located for Ovagen. It is not FDA approved and does not appear to hold independent pharmaceutical registration in Russia; it circulates as a supplement.
How does it work?
Plain-English explanation
The proposed idea, per its more common ovarian-focused marketing, is that Ovagen supports normal ovarian tissue function, potentially relevant to reproductive aging. This is a hypothesis from the developers, not a demonstrated human effect.
Technical explanation
Consistent with other Khavinson-family peptides, the proposed mechanism is short-peptide modulation of gene expression in ovarian tissue (granulosa cells and related structures, per the general bioregulator framework). This has not been independently confirmed, and no pharmacokinetic data for oral administration was identified.
Potential benefits and research applications
Ovarian tissue and reproductive-aging support
What is being investigated: whether Ovagen supports normal ovarian function or reproductive-system aging, per developer and vendor materials. How the effect might occur: proposed gene-regulatory action in ovarian tissue. Evidence: limited animal/mechanistic work attributed to the originating Russian group; no independent replication identified. Strength: weak (Tier 3/4 at best), further weakened by the unresolved liver-vs-ovary labeling conflict described above. Limitation: no controlled human reproductive-outcome data was found.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. No extractable, Ovagen-specific animal dose figures were identified in the sources reviewed.
Practitioner and community-reported protocols
Vendor pages commonly describe 10-20 mg oral capsules, one capsule daily, in cycles of roughly 10-20 days, generally marketed toward women’s reproductive-health or fertility-adjacent longevity use. This is vendor/community-reported (Tier 6) information, and its original clinical source could not be verified.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General ovarian/reproductive support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days.
This is widely repeated online, but its original source could not be verified, and the underlying organ-target claim itself is inconsistent across sellers.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. General risks applicable to unregulated peptide supplements apply: unverified purity and identity, uncertain oral bioavailability, absence of long-term safety monitoring, and supply-chain risks. The organ-target labeling conflict noted above (ovarian vs. hepatic) is itself a safety-relevant concern, since a buyer cannot be certain what a given seller’s “Ovagen” product is actually intended to do or contains.
Regulatory and developmental status
Ovagen is not FDA approved and has no FDA-recognized indication. No independent pharmaceutical registration was identified in Russia; it circulates as a supplement. Status verified as of the review date below.
Frequently asked questions
What is Ovagen?
Ovagen is a short Khavinson-family synthetic peptide most commonly marketed as an ovarian/reproductive-system bioregulator, sold mainly as an oral supplement.
Why do some sites describe Ovagen as a liver peptide?
At least one vendor source labels a product called “Ovagen” as hepatic rather than ovarian. This is a genuine conflict in the available commercial material that PeptideBlog.net could not resolve, and it is documented here rather than silently picking one description.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days; this is vendor/community-reported, not a clinical dose.
Is Ovagen approved by any regulator?
No. No FDA or other formal regulatory approval was identified.
Bottom line
Ovagen is a thinly documented Khavinson-family peptide most often marketed for ovarian/reproductive support, though its organ-target claim is inconsistently described across vendor sources, with at least one conflicting hepatic-peptide label attached to the same name. Whatever underlying research exists is limited to animal/mechanistic work from the originating group, with no independent human clinical evidence or confirmed chemical identifiers.